Valuation : Santhera Pharmaceuticals Holding AG

Market Cap 236M 293M 252M 216M 404M 27.68B 407M 2.8B 1.09B 14.15B 1.1B 1.08B 45.56B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 264M 327M 281M 242M 451M 30.93B 455M 3.12B 1.22B 15.8B 1.23B 1.2B 50.9B EV / Sales 2026 *
2.79x
EV / Sales 2027 * 2.23x
Free-Float
81.52%
Yield 2026 *
-
Yield 2027 * -
1 day+1.61%
1 week+0.39%
Current month+4.69%
1 month+11.41%
3 months+2.63%
6 months-3.22%
Current year+23.97%
1 week 14.62
Extreme 14.62
16.48
1 month 13.9
Extreme 13.9
17.24
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
22.45
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 14/07/2026
Director of Finance/CFO 51 23/02/2025
Chief Operating Officer 55 31/08/2022
Director TitleAgeSince
Chairman 64 29/06/2022
Director/Board Member 58 03/04/2017
Director/Board Member 47 26/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
22/01/24 Buy 30,228 0.2396%
06/07/23 Buy 2,000 0.0016%
11/01/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%+0.39%+14.01%+84.85% 290M
+0.04%+1.44%+80.20%+41.09% 374B
-1.54%-1.61%+25.78%-18.36% 70.56B
+0.47%+3.17%+47.43%+169.71% 12.45B
+1.67%-5.56%-7.74%-8.78% 7.89B
+0.12%-5.68%-13.86%+5.24% 4.98B
+0.12%-6.11%-28.60%+21.23% 4.47B
+2.70%+1.53%-34.44%-1.03% 3B
+0.43%-0.11%-1.76%+38.98% 2.56B
+0.13%-5.79%-28.46%-17.50% 2.01B
Average +0.58%-2.71%+5.26%+31.54% 48.23B
Weighted average by Cap. -0.12%-3.38%+66.34%+33.86%

Financials

2026 *2027 *
Net sales 94.7M 117M 101M 86.64M 162M 11.09B 163M 1.12B 436M 5.67B 440M 431M 18.25B 116M 143M 123M 106M 197M 13.53B 199M 1.37B 532M 6.91B 537M 526M 22.27B
Net income - -
Net Debt 27.7M 34.31M 29.52M 25.34M 47.3M 3.24B 47.68M 328M 128M 1.66B 129M 126M 5.34B 21.4M 26.5M 22.8M 19.58M 36.54M 2.51B 36.83M 253M 98.59M 1.28B 99.53M 97.36M 4.12B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
03/09/26 CHF 15.62 +0.90% 138,100
02/09/26 CHF 15.48 +3.61% 73,450
01/09/26 CHF 14.94 +0.13% 71,518
31/08/26 CHF 14.92 -3.24% 89,471
28/08/26 CHF 15.42 -0.90% 76,441
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.48CHF
Average target price
27.50CHF
Spread / Average Target
+77.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock